Morgan Joseph initiates coverage on Halozyme Therapeutic (Nasdaq: HALO) with a Sell.

Morgan analyst, Eugene Trogan, says, "Halozyme's Enhanze ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE